Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,749.05
(
0.74%
)
US TECH 100
24,124.80
(
0.46%
)
Dow Jones
47,378.05
(
0.92%
)
Brent Oil
99.02
(
0.73%
)
Bitcoin
73,777.06
(
-1.43%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

ThomasS

Send PM Follow Ignore
Followers 12
Posts 2277
Boards Moderated 0
Alias Born 05/05/2005

ThomasS

Re: zipjet post# 59220

Monday, 02/18/2008 1:28:08 AM

Monday, February 18, 2008 1:28:08 AM

Post# of 257251
Copaxone: I think we can all agree that Copaxone is approaching $2B in W/W sales; therefore, why not apply for the 1st generic version? The drug will not disappear overnight, if at all.
Evidently, Sandoz agrees.
A poster on another Board (RPRX, naturally) mentioned that MNTA would never be able to get around Teva's patent, totally ignoring that Sanofi's Lovenox patent is, in all likelihood, being negated as we speak by Teva!




"Illegitimacy is something we should talk about in terms of not having it."

- Dan Quayle

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now